F4 Pharma


Based on solid preclinical and clinical data F4 Pharma is developing the peptide FX06 for different indications associated with vascular leakage. As a first step, the company will concentrate on orphan diseases like transplantation and on diseases in critically ill patients developing Systemic Inflammatory Response Syndrome (SIRS). Smaller and clearly defined patient populations like those suffering from vasoplegic syndrome offer a more targeted development approach.

Recently, orphan drugs have captured a lot of interest by investors because

  • development costs are lower (smaller number of patients, R&D tax credits for development costs, grants for clinical trial expenses),

  • development time is shorter (less studies, advice from regulatory agencies) and

  • return of investment is higher (extended market exclusivity).


©2017 F4 Pharma GmbH i.G.  •  info@f4-pharma.com  •  Page last modified: 04.07.2017